Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Up 0.2 %

Shares of Cara Therapeutics stock opened at $0.26 on Friday. The firm has a market cap of $14.37 million, a PE ratio of -0.15 and a beta of 0.64. Cara Therapeutics has a 52 week low of $0.24 and a 52 week high of $1.31. The business’s fifty day simple moving average is $0.29 and its 200-day simple moving average is $0.33.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CARA. FMR LLC lifted its holdings in shares of Cara Therapeutics by 18.5% in the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 32,789 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Cara Therapeutics during the third quarter worth $29,000. Finally, Disciplined Growth Investors Inc. MN grew its stake in shares of Cara Therapeutics by 6.6% in the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 120,660 shares in the last quarter. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.